post-marketing surveillance raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-17. Anything still debated is marked as such rather than presented as settled.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Louis Circuit Attorney Kimberly Gardner. In February 2023, Circuit Judge David Mason found "clear and convincing evidence" that Johnson was not guilty and ordered his release in February 2023 after 28 years in prison. Schmitt also opposed the release Kevin Strickland, who served 43 years before his release in November 2021, on procedural grounds after Jean Peters-Baker, the prosecutor responsible for reviewing his case, publicly expressed her belief in his innocence. Schmitt's office took the position that the law allowing Peters-Baker to challenge the wrongful conviction required an adversarial process, in which the office of the Attorney General represented the state, as a check on local prosecutorial authority. A judge rejected a motion to retitle the case State of Missouri v. Jean Peters Baker. Despite their procedural argument, assistant attorney general Andrew Clarke said the office believed Strickland to be guilty and that he should remain incarcerated. In August 2021, Schmitt's office issued a subpoena requiring Peters-Baker to turn over any communication with third parties regarding the case, which she characterized as "harassment." After Strickland's release, Peters-Baker said Schmitt's handling of the case amounted to "prosecutorial malpractice" and referred to his procedural position as "profoundly idiotic".
== Society and culture == Golodirsen is one of the very few FDA-approved exon-skipping therapy for Duchenne muscular dystrophy, although the clinical benefits of the medication are yet to established. While the development of golodirsen needed huge financing, it is only applicable to a small subset of people with Duchenne muscular dystrophy. Sarepta Therapeutics has announced that golodirsen will cost in parity with eteplirsen, another medication of a similar kind, which may be as high as US$300,000 per year. Also, the accelerated approval of golodirsen has paved the way for people to have early access to the medication, at the same time, it is shrouded with controversy over a number of issues. A double-blind placebo-controlled confirmatory trial (NCT02500381) is ongoing to resolve the issues.
The Orange Box features five complete games compiled into one retail unit: Half-Life 2 and its two continuations, Episode One and Episode Two; Portal; and Team Fortress 2. All of these games use Valve's Source engine. At its launch the game was priced similar to other AAA video game releases of the era, with it costing $49.95 on PC and $59.95 on console in the United States. The PC release has each game as separate launchables, while the console versions have a main menu where the five games can be selected. Through the Steam platform for the Windows version, the games can collect and report in-depth data such as where the player's character died, completion time, and total victories in multiplayer modes. This data is compiled to generate gameplay statistics for Episode One, Episode Two, and Team Fortress 2. Although Half-Life 2 has the largest proportion of Achievements, there are 99 spread across all five games, exceeding the 50-Achievement limit that Microsoft maintains to feature the most Achievements of any Xbox 360 product. These Achievements include killing a certain number of monsters, finding hidden weapon caches, or other tasks specific to each game. All the games on The Orange Box except Half-Life 2 (on consoles and on PC prior to its 2024 20th anniversary update) contain in-game commentary that can be enabled, allowing the player to listen to the developers discuss the creation and purpose of particular sections and components of each game.
Sources: en.wikipedia.org
As Boer farms were destroyed by the British under their "Scorched Earth" policy—including the systematic destruction of crops and slaughtering of livestock, the burning down of homesteads and farms—to prevent the Boers from resupplying from a home base, many tens of thousands of women and children were forcibly moved into the concentration camps. This was not the first appearance of internment camps, as the Spanish had used internment in Cuba in the Ten Years' War, and the Americans in the Philippine–American War, but the Boer War concentration camp system was the first time that a whole nation had been systematically targeted, and the first in which whole regions had been depopulated. Eventually, there were a total of 45 tented camps built for Boer internees and 64 for black Africans. Of the 28,000 Boer men captured as prisoners of war, 25,630 were sent overseas to prisoner-of-war camps throughout the British Empire. The vast majority of Boers remaining in the local camps were women and children. Around 26,370 Boer women and children were to perish in these concentration camps. Of the more than 120,000 Blacks (and Coloureds) imprisoned too, around 20,000 died. The camps were poorly administered from the outset and became increasingly overcrowded when Kitchener's troops implemented the internment strategy on a vast scale. Conditions were terrible for the health of the internees, mainly due to neglect, poor hygiene and bad sanitation. The supply of all items was unreliable, partly because of the constant disruption of communication lines by the Boers.
Layer-by-layer (LbL) deposition is a thin film fabrication technique. The films are formed by depositing alternating layers of complementary materials with wash steps in between. One of the key advantages of LbL technology compared with other film deposition techniques is its ability to produce highly uniform conformal coatings on both flat and curved surfaces. This can be accomplished by using various techniques such as immersion, spin, spray, electromagnetism, or fluidics.
– the particles are not coated or surface modified. In July 2025, the Scientific Committee on Consumer Safety (SCCS) adopted its fourth opinion (Submission IV), concluding that nano‑hydroxyapatite is safe at concentrations up to 29.5% in toothpaste and up to 10% in mouthwash, under defined particle morphology constraints.
Through discretionary grants, federal agencies set program objectives, eligibility criteria, and funding conditions in Notices of Funding Opportunity (NOFOs), which can shape how artificial intelligence technologies are developed and deployed by funding recipients. Guidance issued by the Office of Management and Budget (OMB) to implement the Executive Order's policies applied risk-management requirements primarily to procurement and agency uses of AI, while generally excluding federal financial assistance programs. In April 2024, the Federal Trade Commission (FTC) announced Operation AI Comply, a cross-agency initiative to ensure that AI products and marketing claims comply with existing consumer-protection, fair-credit, and truth-in-advertising laws. The FTC stated that companies deploying AI systems must "keep their AI claims in check" and warned that false or misleading representations about AI capabilities would be subject to enforcement under the FTC Act. In 2024, a bipartisan House task force released a report on artificial intelligence, while representatives Jay Obernolte and Lori Trahan subsequently developed a bipartisan proposal concerning AI regulation.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.